Loading clinical trials...
Loading clinical trials...
This is a non-randomized, open-label Phase 1b trial to establish the safety and recommended phase 2 dose (RP2D) of bavituximab in combination with pemetrexed and carboplatin in subjects with previousl...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
NCT07259226 · Advanced Breast Cancer, Advanced Gastric Cancer, and more
NCT06889467 · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer (NSCLC), and more
NCT05473156 · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), and more
NCT07283198 · Non Small Cell Lung Cancer (NSCLC)
NCT04772989 · Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), and more
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions